Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Legal Issues Intellectual Property Medical Device

Number To Know … 6,000,000

  • News

Executive Summary

Mirowski Family Ventures will pay $6m to Medtronic to settle attorney’s fees after a patent trial.

$6m is the amount of money Mirowski Family Ventures (MFV) have been ordered to pay Medtronic to settle attorney's fees for a trial involving implantable cardioverter defibrillator (ICD) patents. The patents, owned by MFV and licensed to Boston Scientific, have provoked multiple lawsuits over the last few decades. In 2014, the Federal Circuit Court of Appeals ruled that one such patent was invalid and Medtronic would not need to pay any proposed infringement penalty. The court ruling also made the defendants responsible for Medtronic’s $6m attorney fees.

For more information on this development, see Medtech Insight's article here.

Table

View full table

Topics

Tags:
Legal Issues Intellectual Property Medical Device
Latest Headlines

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

It’s Been Over 1100 Days Since MCIT, Still No TCET In Sight

Mini-Slings Are Comparable To Traditional Ones To Treat Incontinence, FDA Says

Ekso's Exoskeleton Receives Medicare Coverage, Paves Way To Faster Rehabilitation

See All
UsernamePublicRestriction

Register

MT104695

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By